328 related articles for article (PubMed ID: 20078884)
1. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.
Schindler M; Rajan D; Banning C; Wimmer P; Koppensteiner H; Iwanski A; Specht A; Sauter D; Dobner T; Kirchhoff F
Retrovirology; 2010 Jan; 7():1. PubMed ID: 20078884
[TBL] [Abstract][Full Text] [Related]
2. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
3. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.
Andrew AJ; Miyagi E; Kao S; Strebel K
Retrovirology; 2009 Sep; 6():80. PubMed ID: 19737401
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu.
Goffinet C; Homann S; Ambiel I; Tibroni N; Rupp D; Keppler OT; Fackler OT
J Virol; 2010 Apr; 84(8):4089-94. PubMed ID: 20147395
[TBL] [Abstract][Full Text] [Related]
5. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
6. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
[TBL] [Abstract][Full Text] [Related]
7. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
[TBL] [Abstract][Full Text] [Related]
10. Anti-tetherin activities in Vpu-expressing primate lentiviruses.
Yang SJ; Lopez LA; Hauser H; Exline CM; Haworth KG; Cannon PM
Retrovirology; 2010 Feb; 7():13. PubMed ID: 20167081
[TBL] [Abstract][Full Text] [Related]
11. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
12. Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.
Mack K; Starz K; Sauter D; Langer S; Bibollet-Ruche F; Learn GH; Stürzel CM; Leoz M; Plantier JC; Geyer M; Hahn BH; Kirchhoff F
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077643
[TBL] [Abstract][Full Text] [Related]
13. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.
Jolly C; Booth NJ; Neil SJ
J Virol; 2010 Dec; 84(23):12185-99. PubMed ID: 20861257
[TBL] [Abstract][Full Text] [Related]
14. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
15. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
Mitchell RS; Katsura C; Skasko MA; Fitzpatrick K; Lau D; Ruiz A; Stephens EB; Margottin-Goguet F; Benarous R; Guatelli JC
PLoS Pathog; 2009 May; 5(5):e1000450. PubMed ID: 19478868
[TBL] [Abstract][Full Text] [Related]
16. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
[TBL] [Abstract][Full Text] [Related]
17. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
18. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
Lucas TM; Janaka SK; Stephens EB; Johnson MC
PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
[TBL] [Abstract][Full Text] [Related]
19. Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.
Jafari M; Guatelli J; Lewinski MK
J Virol; 2014 May; 88(9):5062-78. PubMed ID: 24574397
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
